Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: A prospective randomized study

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 10, 2014, Pages 1325-1335

  Osonoi, Takeshi ^a   Saito, Miyoko ^a   Tamasawa, Atsuko ^a   Ishida, Hidenori ^a   Osonoi, Yusuke ^a  

^a Naka Kinen Clinic   (Japan)

Author keywords

Acarbose; Blood glucose fluctuations; Continuous glucose monitoring; Mitiglinide; Mitiglinide voglibose combination; Sitagliptin

Indexed keywords

ACARBOSE; GLUCOSE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; METFORMIN; MITIGLINIDE; PIOGLITAZONE; SITAGLIPTIN; VOGLIBOSE; C PEPTIDE; INTERLEUKIN 18; INTERLEUKIN 6; MALONALDEHYDE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOOD GLUCOSE METER; BLOOD GLUCOSE MONITORING; BLOOD SAMPLING; CLINICAL ARTICLE; CONTINUOUS GLUCOSE MONITORING DEVICE; CONTROLLED STUDY; DIABETIC DIET; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIARRHEA; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; FASTING PLASMA GLUCOSE; FEMALE; GLYCEMIC CONTROL; GLYCEMIC INDEX; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; JAPANESE (PEOPLE); KINESIOTHERAPY; LOW BACK PAIN; MALE; METABOLIC PARAMETERS; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL;

ACARBOSE; BLOOD GLUCOSE FLUCTUATIONS; CONTINUOUS GLUCOSE MONITORING; MITIGLINIDE; MITIGLINIDE/VOGLIBOSE COMBINATION; SITAGLIPTIN;

ACARBOSE; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INOSITOL; ISOINDOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRAZINES; SERUM ALBUMIN; TRIAZOLES;

EID: 84902293971     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.920323     Document Type: Article

References (34)

1. The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 1999;354:617-21
2. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-83
3. Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999;22:920-4
4. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
5. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
6. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39
7. Ceriello A, Ihnat MA. 'Glycaemic variability': a new therapeutic challenge in diabetes and the critical care setting. Diabet Med 2010;27:862-7
8. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486-94
9. Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004;25:10-16
10. Aoki K, Masuda K, Miyazaki T, et al. Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men. Endocr J 2010;57:667-72
11. Kusunoki Y, Katsuno T, Myojin M, et al. Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin. Endocr J 2013;60:431-9
12. Narita T, Yokoyama H, Yamashita R, et al. Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients. Diabetes Obes Metab 2012;14:283-7
13. Zheng MY, Yang JH, Shan CY, et al. Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report. Cardiovasc Diabetol 2013;12:73
14. Inagaki N, Watada H, Murai M, et al. Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2013;15:833-43
15. International Diabetes Federation. 2011 Guideline for management of postmeal glucose in diabetes. International Diabetes Federation; Brussels, Europe: 2011
16. Ahren B. Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes Metab Syndr Obes 2010;3:31-41
17. Dhillon S. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010;70:489-512
18. Malaisse WJ. Mitiglinide: a rapid-and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients. Expert Opin Pharmacother 2008;9:2691-8
19. Phillippe HM, Wargo KA. Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2010;44:1615-23
20. Inoue M. Tighter control of postprandial hyperglycemia with mitiglinide/voglibose fixed-dose combination in Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother 2012;13:2257-68
21. Ono Y, Kameda H, Cho KY. Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother 2013;14:361-70
22. Ono Y, Nakamura A, Cho KY, et al. The glycemic/metabolic responses to meal tolerance tests at breakfast, lunch and dinner, and effects of the mitiglinide/voglibose fixed-dose combination on postprandial profiles in Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother 2014;15:311-24
23. Ohta A, Ohshige T, Sakai K, et al. Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-näive Japanese patients with type 2 diabetes. Expert Opin Pharmacother 2013;14:2315-22
24. Pharmaceutical and Medical Devices Agency. Deliberation Report. March 23, 2011. (Voglibose/Mitiglinide Tablets). 2011
25. Kishimoto M, Noda M. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers. Cardiovasc Diabetol 2011;10:115
26. Kurozumi A, Okada Y, Mori H, et al. Efficacy of alpha-glucosidase inhibitors combined with dipeptidyl-peptidase-4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring. J Diabetes Investig 2013;4:393-8
27. Mori Y, Taniguchi Y, Miyazaki S, et al. Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy. Diabetes Technol Ther 2013;15:237-40
28. Sakamoto M, Nishimura R, Irako T, et al. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovasc Diabetol 2012;11:92
29. Tsujino D, Nishimura R, Taki K, et al. Comparing the efficacy of alpha-glucosidase inhibitors in suppressing postprandial hyperglycemia using continuous glucose monitoring: a pilot study-the MAJOR study. Diabetes Technol Ther 2011;13:303-8
30. Zhou J, Li H, Zhang X, et al. Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in Chinese antihyperglycemic agent-naive subjects with type 2 diabetes. Diabetes Technol Ther 2013;15:481-8
31. Seo C, Sakamoto M, Nishimura R, et al. Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study. Diabetes Technol Ther 2013;15:378-85
32. Monnier L, Colette C, Dunseath GJ, et al. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007;30:263-9
33. Buscemi S, Mattina A, Genova G, et al. Seven-day subcutaneous continuous glucose monitoring demonstrates that treatment with acarbose attenuates late dumping syndrome in a woman with gastrectomy for gastric cancer. Diabetes Res Clin Pract 2013;99:e1-2
34. Osonoi T, Hasumi S, Tokushima M, et al. [Concomitant effects of a rapid and short acting insulin secretagogues mitiglinide in type 2 diabetes patients with inadequate control with alpha glucosidase inhibitors monotherapy-Phase III open label study-]. Jpn Pharmacol Ther 2007;35:S93-104; In Japanese